T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 10.1056/nejmoa0903812 2 P igs have been hypothesized to act as a mixing vessel for the reassortment of avian, swine, and human influenza viruses and might play an important role in the emergence of novel influenza viruses capable of causing a human pandemic. [1] [2] [3] Recent reports of widespread transmission of swine-origin influenza A (H1N1) viruses in humans in Mexico, the United States, and elsewhere highlight this ever-present threat to global public health. 4, 5 Between the 1930s and the 1990s, the most commonly circulating swine influenza virus among pigs -classic swine influenza A (H1N1) -underwent little change. However, by the late 1990s, multiple strains and subtypes (H1N1, H3N2, and H1N2) of triple-reassortant swine influenza A (H1) viruses -whose genomes included combinations of avian, human, and swine influenza virus gene segments -had emerged and became predominant among North American pig herds. 6, 7 Influenza virus infection was identified as a cause of febrile respiratory illness in pigs as early as 1931, 3 years before influenza viruses were identified as a cause of illness in people. 8 Classic swine influenza viruses are enzootic among pigs in North America. 9, 10 Cases and clusters of human infections with swine influenza viruses have been reported sporadically in the United States since the 1970s. 4, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Worldwide, more than 50 cases of swine influenza virus infection in humans, most due to classic swine influenza virus, have been documented in the past 35 years, 4, 23, 25, [28] [29] [30] and serologic studies suggest that people with occupational swine exposure are at highest risk for infection. 22, 24, 31, 32 Before the current epidemic of swine-origin influenza A (H1N1) viruses, illness from classic swine influenza viruses, including seven deaths, had been reported in both previously healthy persons and those with preexisting medical conditions (including pregnancy). 13, 16, 17, 20, 21, 27, 29 Signs and symptoms of infection with classic swine influenza virus in humans are often indistinguishable from those of infection with human influenza viruses. 29 Until April 2009, only limited, nonsustained human-to-human transmission of swine influenza virus had been reported. 19, 33, 34 Outside the United States, there have been two published case reports of human infection with triple-reassortant swine influenza A (H1) viruses (both subtype H3N2). 25, 35 
Me thods

Surveillance, Reporting, and Data Collection
A confirmed case of human infection with triplereassortant swine influenza A (H1) viruses was defined as any case with laboratory confirmation at the CDC (see the Laboratory Confirmation section below). Clinical and demographic information about the first three patients identified (Patients 1, 2, and 3) were obtained before 2007, the year when human infection with a novel influenza A virus became a nationally notifiable disease and systematic data collection was initiated. The infection in Patient 1 was jointly investigated by the Wisconsin State Division of Public Health and the CDC and has been reported previously. 23 Epidemiologic data for Patient 2 were limited, since the family declined to participate in a case investigation. The Iowa State Department of Public Health and the CDC collaborated to conduct an investigation of the illness in Patient 3.
Cases of human infection with a novel influenza A virus are reported to the CDC by state public health laboratories in conjunction with state public health departments through the Nationally Notifiable Diseases Surveillance System (see Descriptive data were analyzed with the use of Stata statistical software (version 8) . The analy sis of data presented in this report was not subject to review by the institutional review board, and the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) did not apply because the collection, analysis, and dissemination of data for human cases of novel influenza virus infection is considered a public health surveillance activity.
Laboratory Confirmation
All patients in this series had respiratory samples collected during their illness, which were submitted to their state public health laboratories for microbiologic testing. All but one patient (Patient 7) initially received a diagnosis of infection with an influenza A virus that could not be subtyped, on Yes * Direct contact refers to touching or handling a pig; close proximity refers to standing within 1.83 m (6 ft) of a pig, without known direct contact; near vicinity refers to presence of pigs on the premises but not in close proximity; epidemiologically linked refers to a person who is epidemiologically linked to another person with a confirmed or suspected infection; and unknown refers to unknown contact or unavailable contact information.
the basis of reverse-transcriptase-polymerasechain-reaction (RT-PCR) testing. (Influenza A viruses that cannot be subtyped are defined as those for which the subtype cannot be determined with the use of standard laboratory methods and reagents for circulating human influenza A virus strains -subtype H1N1 or H3N2.) The clinical specimen obtained from Patient 7 was found to be positive for influenza A (H1N2) on viral culture performed at the Michigan State Public Health Laboratory and was then sent to the CDC for further testing. Samples of influenza A viruses that cannot be subtyped are routinely forwarded to the Influenza Division laboratories at the CDC for further characterization and sequencing. At the CDC, all 11 cases of swine influenza virus infection were confirmed and viruses subtyped with the use of real-time RT-PCR and the hemagglutination-inhibition assay. 37, 38 For swine influenza virus detected in respiratory-fluid samples from patients, complete genome-sequence analysis was performed on amplified RNA to determine the constellation of genes and whether the identified swine influenza virus was a triple-reassortant virus containing gene segments from swine, avian, and human influenza viruses. The GenBank accession numbers of five triple-reassortant swine influenza A (H1) viral isolates are listed in the Supplementary Appendix. The internal gene components of a triple-reassortant swine influenza A (H1) virus isolated from ill pigs associated with both patients in Ohio (Patients 4 and 5) have recently been reported. 28 Susceptibility to antiviral drugs, the adamantanes (amantadine and rimantadine), was assessed by means of the pyrosequencing assay 39 with the use of viral RNA extracted from the original clinical specimens, viral isolates, or both. Susceptibility of the viral isolates to the neuraminidase inhibitors oseltamivir and zanamivir was assessed by means of the chemiluminescent neuraminidase-inhibition assay, with the use of the NAStar Kit, as previously described. 40 
R esult s
The demographic and epidemiologic characteristics of the patients and their illnesses, including the incubation period and source of swine exposure, are listed in Table 1 . The median age of the patients was 10 years (range, 16 months to 48 years); eight patients were younger than 18 years of age. Seven of the 11 patients (64%) were male. Patients 4 and 5 were a father-daughter pair. Patient 3 was part of a family with three other members who had suspected, but not laboratory-confirmed, cases of infection with swine influenza virus. All patients resided in either the midwestern or southern United States. 41 Four of the 11 cases (36%) were reported in August, 1 (9%) in October, 2 (18%) in November, 1 (9%) in December, 2 (18%) in January, and 1 (9%) in February.
Exposures to pigs occurred on pig farms (for three patients), at agricultural fairs (for four patients), at a live-animal market (for one patient), and in a custom slaughterhouse (for one patient). In 8 of the 11 cases (73%), pigs were reported to have shown signs of respiratory illness. Five of the 11 patients (45%) touched pigs, 3 patients (27%) came within 1.83 m (6 ft) of pigs but had no known direct contact, and 1 patient (9%) attended a fair but did not visit areas where pigs were exhibited. The exposure was unknown for one patient (9%), and another patient (9%) was epidemiologically linked to a person with a suspected case of infection who had had direct contact with ill pigs -suggesting limited human-to-human transmission of a triple-reassortant swine influenza A (H1) virus. Among the seven patients with exposure to pigs or venues with pigs at a discrete time (known within 1 day), the median incubation period (the interval between the most recent exposure and the onset of illness) was 3.5 days (range, 3 to 9).
The clinical characteristics of the patients are shown in Table 2 . Four of the 11 patients (36%) had a preexisting medical condition: asthma (Patients 6 and 10), an uncharacterized immunodeficiency (Patient 2), or eczema (Patient 11). At least three patients had received current-season influenza vaccine in the season when the triple-reassortant swine influenza A (H1) virus infection was diagnosed; two of the three did not require hospitalization. Among the 10 patients for whom clinical information was available, symptoms included fever (9 patients), cough (10 patients), headache (6 patients), sore throat (6 patients), and diarrhea (3 patients). Myalgia, vomiting, and shortness of breath were reported in two patients each; one patient had conjunctivitis. Among the six patients whose temperature had been reported, the median was 39.7°C (103.5°F) (range, 38.5 to 40.4 [101.3 to 104.8] Four patients (Patients 3, 6, 7, and 9) were hospitalized because of the severity of their illness. In Patients 3 and 7, the disease was self-limited. Patient 3, a 4-year-old, previously healthy girl, was hospitalized because of dehydration and a need for medical monitoring after a 3-day history of fever (temperature, 39.2 to 39.9°C [102.5 to 103.9°F]), vomiting, cough, headache, and congestion; a rapid influenza test was positive for influenza A virus (see the Supplementary Appendix) on day 2 of hospitalization, but she was not treated with oseltamivir. She was discharged from the hospital, fully recovered, after 3 days. Patient 7, a 16-month-old, previously healthy boy, was hospitalized for 1 day for dehydration; he presented with fever (38.5°C [101.3°F]), cough, sore throat, rhinorrhea, and anorexia. A rapid influenza test was positive for influenza A virus, but he was not treated with oseltamivir.
In Patients 6 and 9, the disease was severe and prolonged. Patient 6, a 48-year-old woman with a history of smoking, gastroesophageal reflux disease, and asthma controlled with inhaled corticosteroids, was hospitalized after a 2-day history of fever, chills, cough, and subsequent cyanosis. She underwent intubation and mechanical ventilation for pneumonia and respiratory failure on admission. Specimens from bronchoscopy and bronchoalveolar lavage, initially performed 7 days after admission, yielded influenza A virus on viral culture and Pseudomonas aeruginosa on bacterial culture. The patient was treated with multiple broadspectrum antibiotics and oseltamivir (starting on day 11 of hospitalization) and was discharged, in improved condition, on day 19. Patient 9, a 26-year-old, previously healthy woman, was hospitalized with pneumonia and sepsis after presenting with a 3-day history of fever (a temperature as high as 40.4°C [104.8°F]), cough, vomiting, diarrhea, shortness of breath, and evidence of hypoxia (oxygen saturation, 86%). Initial laboratory testing showed leukopenia (white-cell count, 2100 per cubic millimeter) and thrombocytopenia (platelet count, 135,000 per cubic millimeter). Both viral culture and RT-PCR testing performed on a nasopharyngeal-wash specimen collected on day 2 of hospitalization were positive for influenza A virus. The hospital course was complicated by respiratory failure requiring invasive mechanical ventilation, hypotension requiring a brief course of inotropic medication, and progression to multilobar pneumonia.
The patient was treated with multiple broad-spectrum antibiotics and oseltamivir (beginning on day 19 of hospitalization). She was discharged in improved condition approximately 30 days after admission and eventually had a full recovery.
Of the four patients who underwent chest radiography, the two who were critically ill (Patients 6 and 9) had abnormal findings that were consistent with pneumonia. In addition to these two critically ill patients, two outpatients were treated with oseltamivir (Patient 5, who was treated within 1 day after the onset of symptoms, and Patient 4, who was treated within 3 days). All patients, including the four with severe disease requiring hospitalization, recovered from their illness. Three of four patients with complete blood counts performed during the course of their disease had abnormal findings; two had leukopenia (a white-cell count of <5000 per cubic millimeter), one had lymphopenia (a total lymphocyte count of <800 per cubic millimeter or a total whitecell count with <15% lymphocytes), and one had thrombocytopenia (a total platelet count of <150,000 per cubic millimeter).
Results of laboratory and virologic testing performed by hospital laboratories and state public health laboratories are listed in Table 3 . The results of rapid influenza point-of-care tests were positive in seven of the eight patients who underwent testing by this method. The presence of influenza A virus was initially detected by means of rapid influenza point-of-care testing in 64% of patients, viral culture in 18%, and RT-PCR testing in 9%; one patient (9% of the total) was negative for the virus on rapid testing but was positive on viral culture. Of the five patients who underwent both rapid influenza point-of-care testing and viral culture, three had positive results for both tests.
The CDC confirmed that all 11 patients had infection with triple-reassortant swine influenza A (H1) viruses. The eight individual gene segments found in all 11 viral isolates are shown in Figure 1 . With regard to the triple-reassortant swine influenza A subtype, 10 of the 11 patients (91%) were infected with viral subtype H1N1, and 1 patient (9%) was infected with H1N2.
The hemagglutinin (HA) genes of the triplereassortant swine influenza A (H1) viruses isolated from five patients in this series were found to come from two different phylogenetic lineages currently circulating in North American swine: swH1-beta and swH1-gamma 28 (see Figure 1 in the Supplementary Appendix). Although each lineage has 98 to 100% identical amino acids within itself, the two lineages have diverged from one another by approximately 50 amino acids in the HA gene since their establishment and differ from circulating human seasonal influenza (H1) viruses by more than 100 amino acids. Preliminary data suggest that there is no cross-reactivity between ferret antiserum raised against triple-reassortant swine influenza A (H1) viral isolates and contemporary seasonal human influenza A (H1) viruses. All viral isolates from the 11 patients in this series were susceptible to both adamantanes (amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir and zanamivir).
Discussion
In this report, we describe the clinical and epidemiologic characteristics of 11 cases of laboratoryconfirmed infection with triple-reassortant swine influenza A (H1) viruses, which were identified and reported in the United States before the current epidemic of swine-origin influenza A (H1N1) viruses in humans. The patients' exposures to pigs or their environments varied widely in setting and degree, and almost half the patients had not directly touched pigs. The median incubation period was 3.5 days (range, 3 to 9) from the most recent exposure to pigs or their environment, but in general it appeared to be longer than the incubation period for seasonal influenza. 42 However, exposure to a human with a triple-reassortant swine influenza A (H1) virus as the source of infection could not be ruled out as a possible explanation for the apparently longer incubation period. The most frequent signs and symptoms in the patients were nonspecific and indistinguishable from those of human influenza. However, some of the patients with triple-reassortant swine influenza A (H1) viruses had evidence of severe lower respiratory tract illness and signs that are unusual for influenza, such as diarrhea. Although all patients recovered, a wide spectrum of clinical severity was seen, including two cases of critical illness, one of which occurred in a previously healthy woman.
Although the causes of the increased case reports since December 2005 are unclear, improved virologic surveillance and testing capacity in state public health laboratories and heightened awareness of novel reporting requirements for cases of influenza A may be contributing factors. Alterna- tively, recent increases in case reporting might reflect a true increase in human infections due to changes in zoonotic transmission arising from recent genetic evolution in circulating triple-reassortant swine influenza A (H1) viruses. The phylogenetic data indicate that more than one currently circulating lineage of North American triple-reassortant swine influenza A (H1) viruses has been responsible for recent human infections, with no evidence of adaptive changes shared among them to explain the increase in detected cases. Few, if any, patients in this series were initially suspected of having swine influenza virus infection. Most cases were discovered through virologic testing of respiratory specimens as part of routine seasonal influenza surveillance, highlighting the importance of routine influenza surveillance in the detection of human infections with either seasonal influenza virus or novel influenza virus of animal origin. Although the incidence of infections with triple-reassortant swine influenza A (H1) viruses in the general population is unknown, the number of cases in our series is most likely an underestimate of the true incidence of swine influenza virus infections in the United States. Several seroepidemiologic studies have consistently shown a higher risk of infection with classic swine influenza virus in occupationally exposed populations than in the general population. 22, 24, 32 Given the zoonotic potential of influenza viruses, clinicians should consider animal influenza virus infections in the differential diagnosis for patients presenting with febrile respiratory illness and a recent history of exposure (direct, close, distant, or epidemiologically linked) to swine, poultry, or wild birds (e.g., at agricultural fairs or on farms), 43 especially when human influenza viruses are not circulating in the community. However, during periods when there is evidence of efficient human-to-human transmission of a novel influenza A virus in the community, clinicians should have a low threshold for suspecting, diagnosing, and treating infection appropriately on the basis of the most current recommendations (www.cdc.gov/flu). Clinicians who suspect swine or other zoonotic influenza virus infections in patients with acute respiratory illness should contact their state or local health department to facilitate appropriate specimen collection and timely diagnostic testing at a state public health laboratory. 4 Our findings underscore the need for close communication and collaboration between human and animal health agencies for ongoing surveillance, investigation, research, prevention, and control efforts. In the context of current reports of epidemic swine-origin influenza A (H1N1) viruses in the United States and Mexico 4,5 and global concern regarding the emergence of a human influenza pandemic of animal-influenza origin, epidemiologic and laboratory surveillance of interspecies transmission of influenza viruses should be increased, especially in environments in which humans and swine are routinely exposed to each other. Cases of infection in persons who have been exposed to pigs may be sentinels for early zoonotic transmission of novel triple-reassortant swine influenza A (H1) viruses to humans. Consequently, surveillance in settings involving pigs might facilitate early identification and joint responses of public health and animal health agencies to contain potential outbreaks before widespread community transmission occurs. The mechanism and relative efficiency of indirect and remote exposures to swine influenza (through close proximity, fomites, aerosols, or person-to-person transmission) in the acquisition of human infection with triple-reassortant swine influenza A (H1) viruses require further study. Although uncommon, such cases are likely to continue to occur sporadically, since the triple-reassortant swine influenza A (H1) viruses are endemic in North American swine herds. Clinical and epidemiologic features of human illness, including the usefulness of rapid influenza point-of-care testing and any determinants of antiviral resistance, should continue to be assessed. Our data are subject to several limitations. Cases of infection with triple-reassortant swine influenza A (H1) viruses were reported through passive influenza surveillance systems; therefore additional cases might have occurred that were not identified. Overall, few patients with influenzalike symptoms are tested for influenza, and even fewer would undergo specific testing that would lead to a diagnosis of infection with triple-reassortant swine influenza A (H1) virus (with severe infections perhaps more likely to be diagnosed).
Complete clinical and epidemiologic data were not available for some cases, especially those identified before the start of systematic data collection.
As recent events suggest, the generation of novel influenza viruses through the reassortment of swine influenza viruses with other human and animal influenza viruses may be inevitable. 7 In this context, the possibility of novel influenza viruses causing epidemic and pandemic disease in large populations of immunologically susceptible humans remains a major ongoing public health threat. Consequently, during interpandemic periods, all human infections with influenza viruses of animal origin, even those that appear to be clinically mild, warrant a thorough public health investigation to assess the epidemiologic and clinical risk to humans. 
